Article
Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Jul 2026
Camilleri G M, Loriot M A, Teuff G Le, Thuillier F, Bouche O, Narjoz C, Abdelghani M Ben, Herve C, Corbinais S, Locher C, Lecomte T, Villemin M, Tougeron D, Lepage C, Peytier A, Moussaddaq A S, Dubreuil O, Mabro M, Desrame J, Carvalho N De Sousa, Boige V
Abstract excerpt
BACKGROUND: Pre-treatment screening for dihydropyrimidine dehydrogenase (DPD) deficiency based on plasma uracil concentration ([U]) is mandatory in France before fluoropyrimidine (FP) administration. However, dose-adjustment strategies according to [U] in case of partial DPD deficiency remain empirical, heterogeneous across centers and lacking clear recommendations. METHODS: This national, multicenter, open-label...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.